Anti-Influenza A Virus Effect of Hypericum perforatum L. Extract

To study the antiviral effect of Hypericum perforatum L. extract (HPE) on influenza A virus (IAV) (H1N1) in vitro and in vivo. Cytopathic effect (CPE) and neutral red (NR) dye uptake were used to examine the antiviral effect of HPE on Madin Darby Canine Kidney (MDCK) cells which were infected with IAV in vitro. HPE was effective against influenza A virus (IAV) in vitro, with a 50% effective concentration (EC50) of 40 μg/mL. The mean 50% cytotoxic concentration (CC50) in the MDCK used in these experiments was 1.5 mg/mL. Ribavirin was run in parallel with EC50 values of 5.0 μg/mL; the mean CC50 for ribavirin was 520 μg/mL. Oral gavage administrations of HPE or ribavirin to mice infected with the IAV were highly effective in preventing death, slowing the decline of arterial oxygen saturation, inhibiting lung consolidation and reducing lung virus titers. The minimum effective dose of HPE in these studies was 31.25 mg/kg/day, which was administered twice daily for 5 d beginning 4 h prior to virus exposure. Below a dosage of 2000 mg/kg/day, almost all treated mice survived, which suggests that HPE is of low toxicity. Ribavirin's minimum effective dose was 40 mg/kg/day with the LD50 determined to be 200 mg/kg/day. Delay of the initiation of either HPE or ribavirin therapy, using approximately 1/3 LD50 dose each time, could still be protective as late as 48 h after exposure to the IAV. While both agents appeared to have similar efficacy against IAV infections, HPE was considered to be less toxic and may warrant further evaluation as a possible therapy for influenza.     

Anti-influenza A virus effect of Hypericum perforatum L. extract

To study the antiviral effect of Hypericum perforatum L. extract (HPE) on influenza A virus (IAV) (H₁N₁) in vitro and in vivo. Cytopathic effect (CPE) and neutral red (NR) dye uptake were used to examine the antiviral effect of HPE on Madin Darby Canine Kidney (MDCK) cells which were infected with IAV in vitro. HPE was effective against influenza A virus (IAV) in vitro, with a 50% effective concentration (EC₅₀) of 40 μg/mL. The mean 50% cytotoxic concentration (CC₅₀) in the MDCK used in these experiments was 1.5 mg/mL. Ribavirin was run in parallel with EC₅₀ values of 5.0 μg/mL; the mean CC₅₀ for ribavirin was 520 μg/mL. Oral gavage administrations of HPE or ribavirin to mice infected with the IAV were highly effective in preventing death, slowing the decline of arterial oxygen saturation, inhibiting lung consolidation and reducing lung virus titers. The minimum effective dose of HPE in these studies was 31.25 mg/kg/day, which was administered twice daily for 5 d beginning 4 h prior to virus exposure. Below a dosage of 2000 mg/kg/day, almost all treated mice survived, which suggests that HPE is of low toxicity. Ribavirin’s minimum effective dose was 40 mg/kg/day with the LD50 determined to be 200 mg/kg/day. Delay of the initiation of either HPE or ribavirin therapy, using approximately 1/3 LD₅₀ dose each time, could still be protective as late as 48 h after exposure to the IAV. While both agents appeared to have similar efficacy against IAV infections, HPE was considered to be less toxic and may warrant further evaluation as a possible therapy for influenza. Foundation items: One Hundred Person Project of The Chinese Academy of Sciences (2008-287); The Project of Basic Scientific Research Fund for Central Public-Welfare of Institute of Sciences (BRF070402).     

清热消炎复方制剂抗流感病毒作用的研究

为评价清热消炎复方制剂(简称AI)的抗流感病毒活性,我们以病毒唑为对照,通过在体外观察病毒致细胞病变效应(CPE)、MTT细胞染色检查病毒抑制率和检测病毒血凝滴度;在体内观察其对染毒小鼠的死亡保护作用,对小鼠流感病毒性肺炎的抑制作用,以及对小鼠肺内病毒增殖的影响,从而判定其抗流感病毒作用。结果发现AI在160ug/mL时能完全抑制流感病毒在MDCK细胞内的增殖复制作用。体内实验中0.1g/kg,0.5g/kg,1.2g/kg3个剂量均能明显降低染毒小鼠的致死率,延长平均存活时间:降低肺炎小鼠的肺指数和血凝滴度(P<0.01)。其作用与病毒唑相当。结论认为清热消炎复方制剂是一种有效的体内、体外抗流感病毒中药复方制剂。     

Influenza A virus-induced downregulation of miR-26a contributes to reduced IFNα/β production

Innate immunity provides immediate defense against viral infection. Influenza A virus(IAV) is able to get past the first line of defense. Elucidation of the molecular interaction between influenza factors and the newly recognized host players in the innate response might help in our understanding of the root causes of virulence and pathogenicity of IAV. In this study, we show that expression of miR-26 a leads to a significant inhibition of IAV replication. miR-26 a does not directly target IAV genome. Instead, miR-26 a activates the type I interferon(IFN) signaling pathway and promotes the production of IFN-stimulated genes, thus suppressing viral replication. Furthermore,ubiquitin-specific protease 3(USP3), a negative regulator of type I IFN pathway, is targeted by miR-26 a upon IAV challenge. However, miR-26 a is significantly downregulated during IAV infection.Thus, downregulation of miR-26 a is a new strategy evolved by IAV to counteract cellular antiviral responses. Our findings indicate that delivery of miR-26 a may be a potential strategy for anti-IAV therapies.     

Flu DRiPs in MHC Class Ⅰ Immunosurveillance

Since the publication of the DRiP(defective ribosomal product) hypothesis in 1996, numerous studies have addressed the contribution of DRiPs to generating viral antigenic peptides for CD8~+T cell immunosurveillance. Here, we review studies characterizing the generation of antigenic peptides from influenza A virus encoded DRiPs, discuss the many remaining mysteries regarding the nature of their co-translational generation, and speculate on where the future might lead.     

一株达菲耐药的甲型H1N1流感病毒全基因特征分析

目的 分析1株甲型H1N1流感达菲耐药病毒株的全基因特征,为指导流感临床治疗与防控提供依据。方法 采用鸡胚进行病毒分离,提取病毒RNA,通过RT-PCR扩增其全基因组8个基因片段,测定核苷酸序列,利用生物信息软件拼接全基因组序列,绘制基因进化树并分析重要基因位点变异情况。结果 A/Fuzhou/SWL11609/2013(H1N1)流感毒株的8个节段基因均处于2013-2014年度进化簇中,且与A/California/07/2009(H1N1)疫苗株高度同源,8个基因同源性均在97.4%以上;其HA和NA基因与A/Hubei|Wuchang/SWL1322/2013(H1N1)达菲耐药株同源性最高,分别为100.0%和99.6%;初步判断该毒株未发生重配现象,其重要致病性基因位点未发生变异;NA基因中具有H275Y典型达菲耐药位点特征,缺失一个糖基化位点（N386K）,降低了基因结构的稳定性,同时在V241I和N369K的作用下降低了病毒的适应性。结论 本次研究的甲型H1N1流感达菲耐药病毒株表现为低致病性流感病毒特征,但具备较好的人传人能力,需进一步加强监测,谨防耐药株的广泛流行。     

清热消炎复方制剂抗流感病毒作用的研究

为评价清热消炎复方制剂(简称AI)的抗流感病毒活性,我们以病毒唑为对照,通过在体外观察病毒致细胞病变效应(CPE)、MTT细胞染色检查病毒抑制率和检测病毒血凝滴度;在体内观察其对染毒小鼠的死亡保护作用,对小鼠流感病毒性肺炎的抑制作用,以及对小鼠肺内病毒增殖的影响,从而判定其抗流感病毒作用.结果发现AI在160ug/mL时能完全抑制流感病毒在MDCK细胞内的增殖复制作用.体内实验中0.1 g/kg,0.5g/kg,1.2g/kg 3个剂量均能明显降低染毒小鼠的致死率,延长平均存活时间;降低肺炎小鼠的肺指数和血凝滴度(P<0.01).其作用与病毒唑相当.结论认为清热消炎复方制剂是一种有效的体内、体外抗流感病毒中药复方制剂.     

硫代反义寡核苷酸在细胞培养内抗甲型流感病毒活性

为了研究抗流感病毒特异性反义核酸药物,针对Ａ型流感病毒基因组３＇和５＇端保守序列,设计并合成了４条硫代寡核苷酸（ＯＤＮ）：３＇端反义ＯＤＮ（ＩＶ３＾＃）与３＇端正义ＯＤＮ（ＩＶ３Ｓ）,５＇端反义ＯＤＮ（ＩＶ４＾＃）与５＇端正交ＯＤＮ（ＩＶ４Ｓ）。以流感病毒血凝滴度和致细胞病变作用为指标,测定了ＯＤＮｓ在ＭＤＣＫ细胞中对Ａ型流感病毒Ａ／京防／８６－１（Ｈ１Ｎ１）复制的影响。结果表明,与流感病毒基因组     

Tyrosinase and Layer-by-Layer supported tyrosinases in the synthesis of lipophilic catechols with antiinfluenza activity

Catechol derivatives with lipophilic properties have been selectively synthesized by tyrosinase in high yield avoiding long and tedious protection/deprotection steps usually required in traditional procedures. The synthesis was effective also with immobilized tyrosinase able to perform for more runs. The novel catechols were evaluated against influenza A virus, that continue to represent a severe threat worldwide. A significant antiviral activity was observed in derivatives characterized by antioxidant activity and long carbon alkyl side-chains, suggesting the possibility of a new inhibition mechanism based on both redox and lipophilic properties.